Launch Therapeutics
James Cornwall, PhD, has a diverse and extensive work experience in the pharmaceutical industry. James currently serves as the Head of Business Development at Launch Therapeutics since 2022 and at Abingworth since 2021. Prior to that, they were the President of US-Asia Pharma Advisory from 2015 onwards. From 2015 to 2021, they held the role of Chief Business Officer at Nuvelution Pharma Inc, where they oversaw the advancement of late-stage clinical assets and facilitated financing and market access. James also briefly worked as the Senior Vice President at Samsung Bioepis in 2015. Before that, they had a long tenure at Quintiles, where they held various roles, including VP of Corporate Development, Senior Partner, and VP of Operations and Business Development, from 1993 to 2015. Their career in the pharmaceutical industry began at Glaxo in 1988, where they held various clinical research positions. James Cornwall brings a wealth of experience and expertise in business development, strategic partnerships, and clinical research to their current role.
James Cornwall PhD received their BSc in Pharmacology from the University of Bristol in 1984. James then went on to complete their PhD in Neuropsychopharmacology at the same university from 1984 to 1988.
Launch Therapeutics
Launch Therapeutics (Launch Tx) is a clinical development company with a mission to disrupt the late-stage development paradigm, accelerate timelines to regulatory success, and bring new medicines to patients, faster. To deliver this, Launch Tx offers pharmaceutical and biotech partners a variety of innovative models that combine access to capital with deep drug development, medical, clinical operations, regulatory, and commercialization expertise. These models include significant risk financing, clinical co-development, and full in-licensing, all of which offer partners an aligned and efficient approach to realizing the potential of late-stage clinical programs across any therapeutic area. Founded in 2022, Launch Tx is backed by the respected and experienced professionals at Carlyle and its life sciences franchise, Abingworth. By combining the global network of Carlyle and Abingworth with the seasoned team of professionals at Launch Tx, both pharmaceutical and biotech companies have an ideal partner to advance their late-stage clinical programs.